Gamco Investors INC. ET AL cut its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 3.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,315 shares of the company’s stock after selling 1,635 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Eli Lilly And Co were worth $4,208,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in LLY. Global X Management Co. LLC increased its position in shares of Eli Lilly And Co by 10.6% during the 1st quarter. Global X Management Co. LLC now owns 20,268 shares of the company’s stock valued at $1,568,000 after purchasing an additional 1,945 shares during the last quarter. Commerce Bank increased its holdings in Eli Lilly And Co by 10.4% in the 1st quarter. Commerce Bank now owns 113,996 shares of the company’s stock worth $8,820,000 after acquiring an additional 10,757 shares during the last quarter. Bank of Hawaii increased its holdings in Eli Lilly And Co by 62.3% in the 1st quarter. Bank of Hawaii now owns 14,626 shares of the company’s stock worth $1,132,000 after acquiring an additional 5,613 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Eli Lilly And Co by 3.8% in the 1st quarter. Victory Capital Management Inc. now owns 19,693 shares of the company’s stock worth $1,524,000 after acquiring an additional 727 shares during the last quarter. Finally, Wade G W & Inc. increased its holdings in Eli Lilly And Co by 14.9% in the 1st quarter. Wade G W & Inc. now owns 7,803 shares of the company’s stock worth $604,000 after acquiring an additional 1,011 shares during the last quarter. 76.55% of the stock is owned by hedge funds and other institutional investors.

LLY stock opened at $104.62 on Wednesday. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79. The stock has a market cap of $113.47 billion, a price-to-earnings ratio of 21.00, a P/E/G ratio of 1.76 and a beta of 0.27. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $106.49.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.20. The business had revenue of $6.36 billion during the quarter, compared to analyst estimates of $6.05 billion. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.11 EPS. sell-side analysts expect that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, September 10th. Shareholders of record on Wednesday, August 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 2.15%. The ex-dividend date of this dividend is Tuesday, August 14th. Eli Lilly And Co’s payout ratio is presently 52.57%.

Several equities research analysts recently weighed in on the company. BMO Capital Markets reissued a “hold” rating and issued a $78.00 price objective on shares of Eli Lilly And Co in a report on Thursday, May 10th. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b” rating in a report on Friday, June 29th. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Wednesday, July 18th. Bank of America lifted their price objective on Eli Lilly And Co from $90.00 to $94.00 and gave the stock a “neutral” rating in a report on Wednesday, July 25th. Finally, Cantor Fitzgerald lifted their price objective on Eli Lilly And Co from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, July 25th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly And Co has an average rating of “Buy” and an average target price of $100.13.

In related news, SVP Daniel Skovronsky bought 10,000 shares of Eli Lilly And Co stock in a transaction on Thursday, June 14th. The stock was acquired at an average price of $86.22 per share, with a total value of $862,200.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of Eli Lilly And Co stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $105.89, for a total value of $20,648,550.00. Following the transaction, the insider now directly owns 120,160,804 shares of the company’s stock, valued at approximately $12,723,827,535.56. The disclosure for this sale can be found here. Insiders have sold a total of 1,732,813 shares of company stock valued at $168,655,414 in the last ninety days. Insiders own 0.11% of the company’s stock.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Earnings Per Share (EPS) Explained

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.